(Q43296455)

18 November 2017

Inhalative iloprost - pharmacology and clinical application (English)

1 reference

18 November 2017

1 reference

Ralf Ewert

1

1 reference

18 November 2017

Christoph Schäper

2

1 reference

18 November 2017

Michael Halank

3

1 reference

18 November 2017

Sven Gläser

4

1 reference

18 November 2017

Christian F Opitz

5

1 reference

18 November 2017

language of work or name

English

0 references

publication date

1 September 2009

1 reference

Expert Opinion on Pharmacotherapy

18 November 2017

1 reference

18 November 2017

10

1 reference

18 November 2017

13

1 reference

18 November 2017

2195-2207

1 reference

The chemical structure of prostaglandin X (prostacyclin)

18 November 2017

1 reference

https://api.crossref.org/works/10.1517%2F14656560903164228

Prostacyclin and its analogues in the treatment of pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903164228

Iloprost for idiopathic pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903164228

Inhaled iloprost: in primary pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903164228

Iloprost inhalation solution for the treatment of pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903164228

Inhaled iloprost in pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903164228

Inhaled prostanoids in the therapy of pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903164228

Prostacyclin therapies for the treatment of pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903164228

Differential formation of prostacyclin (PGX or PGI2) by layers of the arterial wall. An explanation for the anti-thrombotic properties of vascular endothelium

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903164228

Differential effects of stable prostacyclin analogs on smooth muscle proliferation and cyclic AMP generation in human pulmonary artery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903164228

Pharmacokinetics and pharmacodynamics of radio-labeled iloprost in elderly volunteers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903164228

Aerosolised prostacyclin in adult respiratory distress syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903164228

Pharmacokinetics and metabolism of infused versus inhaled iloprost in isolated rabbit lungs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903164228

Pharmacodynamics and pharmacokinetics of inhaled iloprost, aerosolized by three different devices, in severe pulmonary hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903164228

Inhaled iloprost for severe pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903164228

Ultrasonic versus jet nebulization of iloprost in severe pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903164228

Combination therapy with oral sildenafil and inhaled iloprost for severe pulmonary hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903164228

Inhaled nitric oxide versus aerosolized iloprost in secondary pulmonary hypertension in children with congenital heart disease: vasodilator capacity and cellular mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903164228

Hemodynamic response to sildenafil, nitric oxide, and iloprost in primary pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903164228

Comparison of inhaled iloprost and nitric oxide in patients with pulmonary hypertension during weaning from cardiopulmonary bypass in cardiac surgery: a prospective randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903164228

Short- and long-term effects of inhaled iloprost therapy in children with pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903164228

Amplification of the pulmonary vasodilatory response to inhaled iloprost by subthreshold phosphodiesterase types 3 and 4 inhibition in severe pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903164228

Effect of inhaled iloprost plus oral sildenafil in patients with primary pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903164228

Assessment of the vasodilator response in primary pulmonary hypertension. Comparing prostacyclin and iloprost administered by either infusion or inhalation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903164228

Continuous hemodynamic monitoring in pulmonary hypertensive patients treated with inhaled iloprost

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903164228

Aerosolised iloprost improves pulmonary haemodynamics in patients with primary pulmonary hypertension receiving continuous epoprostenol treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903164228

Long-time survival with HIV-related pulmonary arterial hypertension: a case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903164228

Comparison of acute hemodynamic effects of aerosolized and intravenous iloprost in secondary pulmonary hypertension in children with congenital heart disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903164228

Ventilation-perfusion relationships in pulmonary arterial hypertension: effect of intravenous and inhaled prostacyclin treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903164228

Inhaled iloprost in patients with chronic thromboembolic pulmonary hypertension: effects before and after pulmonary thromboendarterectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903164228

Inhaled iloprost to control residual pulmonary hypertension following pulmonary endarterectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903164228

Iloprost improves hemodynamics in patients with severe chronic cardiac failure and secondary pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903164228

Inhaled aerosolized iloprost in the evaluation of heart transplant candidates--experiences with 45 cases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903164228

Acute hemodynamic effect of inhaled iloprost in pulmonary artery hypertension evaluated with echocardiography.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903164228

Aerosolized iloprost therapy could not replace long-term IV epoprostenol (prostacyclin) administration in severe pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903164228

Inhaled iloprost to treat severe pulmonary hypertension. An uncontrolled trial. German PPH Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903164228

Effects of inhaled iloprost on right ventricular contractility, right ventriculo-vascular coupling and ventricular interdependence: a randomized placebo-controlled trial in an experimental model of acute pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903164228

Right ventricular function in cardiovascular disease, part II: pathophysiology, clinical importance, and management of right ventricular failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903164228

Hemodynamic effects of aerosolized iloprost in pulmonary hypertension at rest and during exercise

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903164228

Continuous haemodynamic monitoring during exercise in patients with pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903164228

Clinical efficacy and survival with first-line inhaled iloprost therapy in patients with idiopathic pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903164228

Effects of nebulised iloprost on pulmonary function and gas exchange in severe pulmonary hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903164228

Long-term treatment of pulmonary hypertension with aerosolized iloprost

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903164228

Bosentan treatment in patients with primary pulmonary hypertension receiving nonparenteral prostanoids

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903164228

Bosentan improves exercise tolerance and Tei index in patients with pulmonary hypertension and prostanoid therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903164228

Oral sildenafil as long-term adjunct therapy to inhaled iloprost in severe pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903164228

Expert opinion on available options treating pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903164228

Iloprost-containing liposomes for aerosol application in pulmonary arterial hypertension: formulation aspects and stability.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903164228

Impact of aerosolized prostacyclin analog for severe pulmonary hypertension in thoracic organ transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903164228

Use of inhaled iloprost in a case of pulmonary hypertension during pediatric congenital heart surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903164228

Intraoperative management of severe pulmonary hypertension during cardiac surgery with inhaled iloprost.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903164228

Inhaled iloprost is a potent acute pulmonary vasodilator in HIV-related severe pulmonary hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903164228

Inhaled prostacyclin and iloprost in severe pulmonary hypertension secondary to lung fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903164228

Treatment of severe pulmonary hypertension with inhaled iloprost

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903164228

Iloprost for chronic thromboembolic pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903164228

Hemodynamic observations in two pulmonary hypertensive patients changing treatment from inhaled iloprost to the oral endothelin-antagonist bosentan

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903164228

Use of long-term combined therapy with inhaled iloprost and oral sildenafil in an adult patient with eisenmenger syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903164228

Successful switch from inhalative iloprost to oral bosentan in portopulmonary hypertension associated with liver cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903164228

Survival of patients with idiopathic pulmonary arterial hypertension after listing for transplantation: impact of iloprost and bosentan treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903164228

Inhaled iloprost for hepatopulmonary syndrome: improvement of hypoxemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903164228

A comparison of the acute hemodynamic effects of inhaled nitric oxide and aerosolized iloprost in primary pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903164228

Long-Term Treatment of Primary Pulmonary Hypertension with Aerosolized Iloprost, a Prostacyclin Analogue

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903164228

Experience with inhaled iloprost and bosentan in portopulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903164228

Combining inhaled iloprost with bosentan in patients with idiopathic pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903164228

10.1517/14656560903164228

21 January 2018

Identifiers

DOI

1 reference

18 November 2017

1 reference